Metabolically-activated drug conjugates to overcome resistance in cancer therapy
Described are combination therapies and metabolically-activated drug conjugates and their use in treating cancer in subjects.
1. A metabolically-activated drug conjugate having the structure:
2. A method of treating a subject who has drug-resistant cancer, the method comprising administering to the subject the metabolically-activated drug conjugate of claim 1 .
3. The method of claim 2 , wherein the cancer is resistant to a cytotoxic agent.
4. A method of treating a subject who has cancer, the method comprising:
administering a round of induction therapy, wherein the round of induction therapy comprises administration of an amount of a cytotoxic agent or radiation therapy sufficient to increase glucose uptake or induce drug resistance in the cancer cells; and
administering a therapeutically effective amount of the metabolically-activated drug conjugate of claim 1 .
5. The method of claim 4 , wherein the metabolically-activated drug conjugate is administered within about 24-240 hours after a final dose of the round of induction therapy.